Biotech News
Related news
ICUSeaStar Medical2026-10-07 12:16 EST
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
JNJJohnson & Johnson2026-09-21 14:33 EST
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
ICCMIceCure Medical2026-09-10 11:58 EST
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
FEMYFEMASYS2026-08-19 13:00 EST
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
VTAKCatheter Precision2026-09-02 20:15 EST
Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean
SGHTSight Sciences2026-08-04 21:38 EST
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System
AORTArtivion2026-07-28 20:10 EST
Artivion to Participate in Upcoming Investor Conferences
XAIRBeyond Air2026-08-31 12:00 EST
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
ICCMIceCure Medical2026-08-20 12:10 EST
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
JNJJohnson & Johnson2026-09-18 11:00 EST
CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy
Artivion
Aortic-Disease Technologies Artivion develops medical devices and implantable tissues for complex aortic and cardiac surgery. Its portfolio is designed around the needs of cardiac and vascular surgeons treating life-threatening aortic disease. Surgical Products The company supplies aortic stent grafts, surgical adhesives, mechanical...
Recent company news
AORTArtivion2026-08-06 20:05 EST
Artivion Reports Second Quarter 2026 Financial Results
AORTArtivion2026-07-28 20:10 EST
Artivion to Participate in Upcoming Investor Conferences
AORTArtivion2026-07-23 20:10 EST
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
AORTArtivion2026-06-29 11:00 EST
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
AORTArtivion2026-06-10 20:10 EST
Artivion to Participate in the 2026 Truist Securities MedTech Conference
Stock data
- Close
- 21.84 USD
- Market cap
- 991.26M USD
- Exchange
- NYSE
- Sector
- MedTech
- Location
- United States